Biotech | March 14, 2026
MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
The protections extend through at least 2035, with the potential for further extensions
The protections extend through at least 2035, with the potential for further extensions
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The FDA classified LifeVac as a Class II medical device
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
Subscribe To Our Newsletter & Stay Updated
